Clinical trial
A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy
NCT01435356 is registered in ClinicalTrials.gov with European Association of Urology Research Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy
- Lead sponsor
- European Association of Urology Research Foundation
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 31, 2011
- Completion date
- April 7, 2017
- Enrollment
- 83 (actual)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.